Valsts: Austrālija
Valoda: angļu
Klimata pārmaiņas: APVMA (Australian Pesticides and Veterinary Medicines Authority)
METHYLPREDNISOLONE ACETATE
AUSRICHTER PTY LTD
methylprednisolone as acetate(34.6mg/mL)
PARENTERAL LIQUID/SOLUTION/SUSPENSION
METHYLPREDNISOLONE ACETATE STEROID-GLUCOCORTICOID Active 40.0 mg/ml
10mL
VM - Veterinary Medicine
AUSRICHTER
CAT | DOG | HORSE | BITCH | CASTRATE | CAT - QUEEN | CAT - TOM | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH
ENDOCRINE SYSTEM
ANTI-INFLAMMATORY AGENT | ARTHRITIS | DERMATITIS | EOSINOPHILIC GRANULOMAS | MUSCULOSKELETAL CONDITIONS | OCULAR CONDITION | PRURITIS | ALLERGIC SKIN DISORDER | ANTIPYRETIC | ARTHRITIS | ARTHROSIS | BONE SORENESS | BRUISING | BURSITIS | EXTERNAL MYOPATHY | GANGRENOUS | INFLAMATION OF SOFT TISSUES AN | INFLAMMATORY RHEUMATIC ARTHRIT | JOINT DISEASE | LIGAMENT SPRAINS | MUSCLE SORENESS | OSTEITIS | OSTEOARTHRITIS | PLATELET ACTIVITY | RHEUMATISM | SKIN DISORDER | SPRAINS | STRAINS | TENDON AND LIGAMENT SPRAINS | TENDON SPRAINS | TENDONITIS | TENOSYNOVITIS | TRAUMATIC JOINT AND CONNECTIVE | TRAUMATIC SWELLING
Poison schedule: 4; Withholding period: WHP: MEAT: Do not administer to horses less than 60 days before slaughter for human consumption.; Host/pest details: CAT: [ANTI-INFLAMMATORY AGENT, ARTHRITIS, DERMATITIS, EOSINOPHILIC GRANULOMAS, MUSCULOSKELETAL CONDITIONS, OCULAR CONDITION, PRURITIS]; DOG: [ANTI-INFLAMMATORY AGENT, ARTHRITIS, DERMATITIS, MUSCULOSKELETAL CONDITIONS, OCULAR CONDITION, PRURITIS]; HORSE: [ANTI-INFLAMMATORY AGENT, ARTHRITIS, DERMATITIS, MUSCULOSKELETAL CONDITIONS, OCULAR CONDITION, PRURITIS]; Poison schedule: 4; Withholding period: ; Host/pest details: CAT: [ANTI-INFLAMMATORY AGENT, ARTHRITIS, DERMATITIS, EOSINOPHILIC GRANULOMAS, MUSCULOSKELETAL CONDITIONS, OCULAR CONDITION, PRURITIS]; DOG: [ANTI-INFLAMMATORY AGENT, ARTHRITIS, DERMATITIS, MUSCULOSKELETAL CONDITIONS, OCULAR CONDITION, PRURITIS]; HORSE: [ANTI-INFLAMMATORY AGENT, ARTHRITIS, DERMATITIS, MUSCULOSKELETAL CONDITIONS, OCULAR CONDITION, PRURITIS]; Suppression of inflammation, arthritic conditions, relief of pruritis and inflammation in dermatitis in dogs, cats and horses. Allergic conditions in dogs and cats, Pain and lameness associated with musculoskeletal conditions, and ocular conditions.Do not use in ulcerative conditions of the cornea (until a negative fluorescein stain has been obtained) or in animals with Cushing’s Disease. See also PRECAUTIONS/ADVERSE REACTIONS on leaflet.
Registered
2023-07-01
PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY BBU DEPREDONE@ INJECTION OF LONG-ACTING PREONISOLONE FOR DOGS, CIWS AND HORSES COMPOSITION: Methylpredmsolone acetate 40 mg/mL (equrvalent to 34.6 mg/mL methylprednisolone); benzyl alcohol 1 ml-/100 mL as preservative. ACTIONS: Prolonged action synthetic anti-mflammatoj sterord wrth mmlmal mrneralocortrcord activity. In this depot form, the sterord IS slowly released and has a therapeutic duration of 2 to 3 weeks. INDICATIONS: Suppression of mflammatron. arthritic condihons: relief of pruritisand mflammation in dermatitis in dogs, cats and horses. A//erg/c conditions in dogs and _cats _ Pruritis associated with contact allergens Systemic allergic conditions are more effective!y treated with an intravenous steroid such as dexamethasone. _Musculoskeletal_ _ conditions. _ Pain and lameness associated with local or systemic nonseptic arthrrtrc conditions; also of benefit rn the management of acuteand chrome synovitrs, tendomtis, bursrtrs, myositis and periostitis. The drug may be administered topically (into the lesion) or systemically. _Ocular _ _conditions. _ Management of inflammatory eye conditions. Subconjunctival administration of the drug results rn a high concentration of the drug and a prolonged duration of therapy in the eye, thus avoiding the frequent administration of steroids that are required wrth other therapeutic preparations _‘fosmophlc_ _ _ _gfanulomas_ _ _ _m_ cats.' These have also been successfully treated by the systemic use of Depredone However, a more beneficial regimen has been observed by the intralesronal injection of triamcinolone acetonide. PRECAUTIONS: Corticosterords tend to decrease chemotachc properties of phagocytes and thus tend to decrease the efficacy of host defence mechanisms They may also tend to modrfy the natural antibody defence mechanisms. Use with caution where severe tissue damage is present It is recommended that rn such cases and where an infective process IS suspected, antibiotic thera Izlasiet visu dokumentu
MATERIAL SAFETY DATA SHEET PRODUCT NAME: DEPREDONE INJECTION Issue Date: 29JAN08 QAF140 Page 1 of 3 STATEMENT OF HAZARDOUS NATURE NOT CLASSIFIED AS HAZARDOUS ACCORDING TO CRITERIA OF NOHSC AUSTRALIA COMPANY DETAILS Company: Jurox Pty Limited, Address: 85 Gardiners Road, Rutherford NSW 2320 Telephone: (02) 4931 8200 or 1800 023 312 Emergency Telephone No.: (02) 4931 8200 or 1800 023 312 Company: Jurox New Zealand Limited Address: 8 Kordel Place, East Tamaki, Auckland Telephone: 0800 587 696 Emergency Telephone No: 0800 587 696 IDENTIFICATION Product Name: Depredone Injection Other Names: Manufacturer’s Product Code: 60840 UN Number: None Allocated Dangerous Goods Class: None Allocated Subsidiary Risk: None Allocated Hazchem Code: None Allocated Poisons Schedule Number: S4 (Aus), PAR1 (NZ) Use: Sterile corticosteroid injection for the suppression of inflammation, arthritic conditions, relief of pruritis and inflammation in dermatitis for horses, dogs and cats. PHYSICAL PROPERTIES / DESCRIPTION Appearance: White suspension in clear colourless liquid Boiling Point/Melting Point: Vapour Pressure: Specific Gravity: Flashpoint: Non-flammable Flammability Limits: Solubility in Water: Miscible pH: 5.0 – 7.0 OTHER PROPERTIES INGREDIENTS CHEMICAL ENTITY CAS NUMBER PROPORTION 6-A-Methyl Prednisolone Acetate 52-21-1 4% Water 7732-18-5 to 100% MATERIAL SAFETY DATA SHEET PRODUCT NAME: DEPREDONE INJECTION Issue Date: 29JAN08 QAF140 Page 2 of 3 HEALTH HAZARD INFORMATION HEALTH EFFECTS ACUTE Swallowed: May result in dizziness, nausea and vomiting. Absorbed through the oral mucosa and gastrointestinal tract. Eye: Moderate irritant Skin: Mild irritant. Absorbed through the skin. Inhaled: Does not present an inhalation problem Injected: Effects will vary in severity according to the quantity involved, from localized site reaction (swelling, pain, redness), to acute systemic reaction. CHRONIC Due to the presence of 6-A-Methyl Prednisoloe Acetate, prolonged or repeated contact may lead to electrolyte imbalance, oedema, hypertension Izlasiet visu dokumentu